TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP announced an investigation into Tenax Therapeutics regarding potential violations of federal securities laws. The investigation focuses on whether the company issued misleading statements related to its Phase 3 LEVEL trial of TNX-103, which failed to meet primary and secondary endpoints.
Key figures
- Drug Name
- TNX-103
- Phase Of Trial
- Phase 3
- Stock drop
- almost 90%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.